Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Caladrius Bio (CLBS)

Caladrius Bio (CLBS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,781
  • Shares Outstanding, K 19,323
  • Annual Sales, $ 0 K
  • Annual Income, $ -19,360 K
  • 60-Month Beta 1.49
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.87
Trade CLBS with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.30
  • Number of Estimates 3
  • High Estimate -0.22
  • Low Estimate -0.46
  • Prior Year -0.47
  • Growth Rate Est. (year over year) +36.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4494 +22.81%
on 09/04/20
2.1100 -15.64%
on 09/16/20
-0.1500 (-7.77%)
since 09/01/20
3-Month
1.4494 +22.81%
on 09/04/20
3.2101 -44.55%
on 07/14/20
+0.0100 (+0.56%)
since 07/01/20
52-Week
1.0500 +69.52%
on 03/19/20
3.6400 -51.10%
on 01/13/20
-0.8800 (-33.08%)
since 10/01/19

Most Recent Stories

More News
Virtual Conference for Life Sciences Companies Broadcast Live September 17th, 2020

Company executives will share corporate vision and answer audience questions at LifeSciencesInvestorForum.com

CLBS : 1.8000 (-0.33%)
Caladrius Biosciences to Present at the Life Sciences Investor Forum on September 17th

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage,...

CLBS : 1.8000 (-0.33%)
Thinking about buying stock in Conduent Inc, Agile Therapeutics, Caladrius Biosciences, Delta Air Lines, or AstraZeneca?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CNDT, AGRX, CLBS, DAL, and AZN.

AZN : 54.67 (-0.24%)
CLBS : 1.8000 (-0.33%)
CNDT : 3.21 (+0.94%)
DAL : 30.98 (+1.31%)
Caladrius Biosciences to Participate in Landmark's 10th Annual Investing for Cures Virtual Forum

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage,...

CLBS : 1.8000 (-0.33%)
Caladrius Biosciences Announces Registration of HONEDRA(R) Trademark and New Patent in Japan

Approval received from the Japan Patent Office to use HONEDRA(R) as brand name for CLBS12 in Critical Limb Ischemia and Buerger's Disease

CLBS : 1.8000 (-0.33%)
Caladrius Biosciences to Present at H.C. Wainwright 22nd Annual Global Investment Virtual Conference

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage,...

CLBS : 1.8000 (-0.33%)
Caladrius Biosciences to Participate in the Advanced Therapies Congress & Expo 2020

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage,...

CLBS : 1.8000 (-0.33%)
Caladrius Biosciences to Present at the LD 500 Virtual Conference on September 1, 2020 at 11:40 AM Eastern Time

BASKING RIDGE, NJ / ACCESSWIRE / August 27, 2020 / Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular...

CLBS : 1.8000 (-0.33%)
Critical Limb Ischemia Drug Market Global Research and analysis 2020 to 2026

The Global Research Report 2020-2026 is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue,...

CLBS : 1.8000 (-0.33%)
CYYNF : 0.6750 (unch)
HEM.VN : 0.005 (-50.00%)
PSTI : 9.87 (-6.27%)
RNUGF : 1.1000 (-3.08%)
Caladrius Biosciences Provides Corporate Update and Reports 2020 Second Quarter Financial Results

Clinical programs advanced and expanded with strengthened cash position

CLBS : 1.8000 (-0.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve...

See More

Key Turning Points

2nd Resistance Point 1.9467
1st Resistance Point 1.8733
Last Price 1.8000
1st Support Level 1.7533
2nd Support Level 1.7067

See More

52-Week High 3.6400
Fibonacci 61.8% 2.6506
Fibonacci 50% 2.3450
Fibonacci 38.2% 2.0394
Last Price 1.8000
52-Week Low 1.0500

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar